articleThe Lancet OncologyApr 16, 2019GREEN OA

Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial

CECathy EngTWTae Won KimJCJohanna C. BendellGAGuillem ArgilésNCNiall C. Tebbutt

The University of Texas MD Anderson Cancer Center · Asan Medical Center · +13 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

557
total citations
FWCI
28.18
Percentile
100%
References
31
Citations per year

Authors

79

Topics & keywords

Topics
Keywords
  • Regorafenib
  • Atezolizumab
  • Medicine
  • Colorectal cancer
  • Open label
  • Internal medicine
  • Oncology
  • Phases of clinical research
No related works found for this paper.

Funding